Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 13/20 | 0.50 |
| ▸ | PPARD | Q03181 | 11/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | PPARG | P37231 | 4/20 | 0.46 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.41 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2818885 | 0.89 | PPARA (0.50) | PPARAPPARDHDAC1PPARGTBXAS1 | |
| SCHEMBL2822396 | 0.83 | PPARA (0.45) | PPARAPPARDHDAC1PPARGHSP90AB1 | |
| SCHEMBL2821397 | 0.82 | PPARA (0.48) | PPARAPPARDPPARGTBXAS1HSP90AB1 | |
| SCHEMBL2822932 | 0.82 | PPARD (0.43) | PPARAPPARDHDAC1PPARGHSP90AB1 | |
| SCHEMBL2820775 | 0.82 | PPARA (0.49) | PPARAPPARDHDAC1PPARG | |
| SCHEMBL2819363 | 0.81 | HSP90AB1 (0.47) | PPARAPPARDHDAC1PPARGTBXAS1 | |
| SCHEMBL2819219 | 0.80 | HSP90AB1 (0.43) | PPARAPPARDHDAC1PPARGTBXAS1 | |
| SCHEMBL2819648 | 0.79 | HDAC1 (0.44) | PPARAPPARDHDAC1HSP90AB1 | |
| SCHEMBL2821752 | 0.79 | CYP19A1 (0.51) | PPARAHDAC1PPARGTBXAS1HSP90AB1 | |
| SCHEMBL2821113 | 0.78 | CYP19A1 (0.52) | PPARAPPARDHDAC1PPARGTBXAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100184815-A1 | AGONISTS OF PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR-ALPHA | MPM ASSET MANAGEMENT INVESTORS 2002 BVIII LLC | 2010-07-22 | — | — | US | claimed |
| WO-2010071813-A1 | AGONISTS OF PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR-α | ARYX THERAPEUTICS, INC. (US) | 2010-06-24 | — | — | WO | claimed |
| US-20100184815-A1 | AGONISTS OF PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR-ALPHA | MPM ASSET MANAGEMENT INVESTORS 2002 BVIII LLC | 2010-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100184815-A1 | AGONISTS OF PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR-ALPHA | PPARA, PPARD, PPARG | PPARA 1/4885PPARD 2/4885HDAC1 1167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.